SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
NCT00608868
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
156
Enrollment
INDUSTRY
Sponsor class
Conditions
Non Small Cell Lung Carcinoma
Interventions
DRUG:
Gefitinib
Sponsor
AstraZeneca